Backus LI, et al. - In this observational cohort analysis, the researchers assessed the impact of sustained virologic response (SVR) achieved with interferon-free direct-acting antiviral (DAA) treatment on all-cause mortality in hepatitis C virus-infected patients without advanced liver disease. The sample consisted of 103,346 genotype 1, 2, and 3, hepatitis C virus–monoinfected patients without advanced liver disease, defined by FIB-4 ≤3.25 and no diagnosis of cirrhosis, hepatic decompensation, or hepatocellular carcinoma or history of liver transplantation, identified from the Veterans Affairs Hepatitis C Clinical Case Registry. In patients without clinically apparent advanced liver disease, successfully treating hepatitis C virus with DAAs translates into a significant mortality benefit.